Lung transplantation has evolved into an effective treatment for progressive respiratory conditions since its experimental beginnings in the early 1960s. The patient who received the first lung transplant in 1963 survived for only 18 days. However, new methods, techniques, and diagnostic criteria have made transplantation a viable and lasting treatment for patients who deteriorate beyond maximal medical therapy.
In the winter issue of The Ochsner Journal, Reinaldo Rampolla, MD, of Ochsner’s Multi-Organ Transplant Institute tracks the evolution of lung transplantation as a treatment for different conditions in an informative review, Lung Transplantation: An Overview of Candidacy and Outcomes.
The article focuses on patient survival rates and the guidelines for including patients on the transplant waiting list, while discussing topics such as posttransplant quality of life, cost, and contraindications for transplantation. Dr. Rampolla stresses that because of lung transplantation’s versatility as a treatment, adapting treatment options and follow-up to individual patients’ lifestyle and pathology optimizes survival rates.
Read the article here.